Allergic reactions, theoretical thrombosis risk when over-corrected in prothrombotic states, and very rarely transmission of infectious agents despite robust viral safety steps. 

Observe during infusion and for a period after administration for rash, pruritus, dyspnoea, hypotension, or chest discomfort. Stop infusion if reactions occur and treat per protocol.

Thrombotic events are uncommon but possible. Use target-based dosing and avoid overshooting in patients with high thrombotic risk.

Only under specialist direction when active bleeding requires targeted fibrinogen replacement as part of comprehensive DIC management.